Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

BACKGROUND

In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type.

METHODS

To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell lines were analyzed. Subsequently, a multicenter study was conducted. Patients with advanced solid tumors lacking standard of care treatment options were included and underwent a pre-treatment tumor biopsy to enable DNA sequencing of 1,977 genes, derive copy number profiles and determine activation status of pS6 and pERK. Treatment benefit was determined according to TTP ratio and RECIST. We tested for associations between treatment benefit and single molecular aberrations, clusters of aberrations and pathway perturbation.

RESULTS

Cell line screens indicated several genes, such as ( = 0.016; Wald test), to be associated with sensitivity to mTOR inhibition. Subsequently 73 patients were included, of which 59 started treatment with everolimus. Response and molecular data were available from 43 patients. aberrations, i.e. copy number loss or mutation, were associated with treatment benefit ( = 0.046; Fisher's exact test).

CONCLUSION

Loss-of-function aberrations in potentially represent a tumor type agnostic biomarker for benefit from everolimus and warrants further confirmation in subsequent studies.